Billiontoone (NASDAQ:BLLN) Hits New 12-Month High – Here’s Why

Billiontoone, Inc. (NASDAQ:BLLN) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $144.27 and last traded at $142.5190, with a volume of 657338 shares changing hands. The stock had previously closed at $137.32.

Key Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Strong quarterly revenue: BillionToOne reported second-quarter revenue of $109.45 million and adjusted earnings of $0.15 per share, matching Wall Street expectations. The company also reiterated full-year 2026 revenue guidance of $450 million to $465 million, indicating continued growth. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
• Positive Sentiment: Analysts remain constructive: BTIG Research and JPMorgan Chase both maintained bullish ratings, using “buy” and “overweight,” respectively. Each firm lowered its price target to $130, which still implies substantial upside from the referenced share price. Benzinga analyst price-target reports
• Neutral Sentiment: Investor focus is on guidance: Coverage of the results highlighted that revenue surged, but management did not increase its full-year forecast. The lack of an outlook raise appears to have disappointed investors who had expected stronger guidance following the quarter. BillionToOne sinks as outlook unchanged despite surging revenue
• Negative Sentiment: Price targets were cut: JPMorgan reduced its target from $145 to $130, while BTIG lowered its target from $142 to $130. Although both firms kept positive ratings, the reductions signal more limited near-term expectations and added pressure to the stock. Benzinga analyst price-target reports
• Negative Sentiment: Insider selling adds an overhang: CEO Oguzhan Atay sold 45,000 shares worth approximately $6.17 million, while insider Shan Riku Sakakibara sold 4,000 shares for about $561,000. The transactions were made under pre-arranged Rule 10b5-1 plans, reducing their signaling value but potentially weighing on sentiment. Billiontoone insider selling reports

Wall Street Analyst Weigh In

BLLN has been the topic of several recent research reports. JPMorgan Chase & Co. decreased their price objective on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. BTIG Research dropped their price objective on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Guggenheim began coverage on shares of Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and a consensus target price of $126.71.

Billiontoone Trading Down 38.9%

The company has a 50 day moving average of $116.61 and a 200 day moving average of $94.28. The firm has a market cap of $4.21 billion and a price-to-earnings ratio of 130.93. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.15. Billiontoone had a return on equity of 12.84% and a net margin of 8.04%.The company had revenue of $109.45 million during the quarter. As a group, research analysts anticipate that Billiontoone, Inc. will post 0.92 EPS for the current year.

Insider Activity

In other Billiontoone news, CEO Oguzhan Atay sold 32,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $136.95, for a total value of $4,450,875.00. Following the transaction, the chief executive officer directly owned 20,000 shares in the company, valued at $2,739,000. The trade was a 61.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nancy Joann Johnson sold 10,582 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the sale, the insider directly owned 21,900 shares in the company, valued at $2,200,293. This represents a 32.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 202,049 shares of company stock valued at $23,496,861. Company insiders own 50.22% of the company’s stock.

Institutional Trading of Billiontoone

A number of hedge funds and other institutional investors have recently made changes to their positions in BLLN. Rossby Financial LCC acquired a new position in Billiontoone during the 4th quarter worth about $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $76,000. Smartleaf Asset Management LLC acquired a new stake in shares of Billiontoone in the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone during the 4th quarter worth $82,000. Finally, Renaissance Capital LLC bought a new position in Billiontoone in the 4th quarter valued at $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.